PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1555504
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1555504
Orally Disintegrating Tablet Market size was valued at USD 13,123.12 Million in 2023, expanding at a CAGR of 8.1% from 2024 to 2032.
An Orally Disintegrating Tablet (ODT) is a type of medication that is designed to dissolve quickly in the mouth without needing water. This can be particularly useful for people who have difficulty swallowing traditional tablets or capsules, such as children or elderly patients.
Orally Disintegrating Tablet Market- Market Dynamics
Increasing improved bioavailability and convenience to use are expected to propel market demand
ODTs can enhance the bioavailability of certain drugs, making them more effective. This is particularly beneficial for medications that require rapid onset of action. ODTs are increasingly used in a variety of therapeutic areas beyond just pediatric and geriatric care, including mental health, allergies, and pain management. This broader application helps drive market growth. Patients often prefer ODTs over traditional tablets due to their ease of use and the reduced need for water. Increased patient compliance can lead to better therapeutic outcomes and, subsequently, higher demand.
Furthermore, ODTs offer a practical solution for patients who have difficulty swallowing traditional tablets or capsules. This includes children, elderly individuals, and those with certain medical conditions. The ease of administration without needing water contributes to higher patient compliance. Innovations in tablet formulation technologies have improved the taste, stability, and efficacy of ODTs. Advances in manufacturing processes allow for more effective and patient-friendly ODTs.
Orally Disintegrating Tablet Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 8.1% over the forecast period (2024-2032)
Based on Drug Type segmentation, the anti-allergic drugs segment was predicted to show maximum market share in the year 2023, owing to growing allergic disorders.
Based on Indication segmentation, the cardiovascular diseases segment was the leading Indication in 2023, owing to the high need for ODTs in cardiovascular therapies.
Based on Distribution Channel segmentation, the hospital pharmacies segment was the leading Distribution Channel segment in 2023, owing to the high demand for ODTs in hospitals.
Based on region, North America was the leading revenue generator in 2023, due to the growing prevalence of chronic diseases.
The Global Orally Disintegrating Tablet Market is segmented based on Drug Type, Indication, Distribution Channel, and Region.
The market is divided into seven categories based on Drug Type: anti-psychotics, anti-epileptics, anti-hypertensives, anxiolytics, anti-allergic drugs, proton pump inhibitors, and others. The anti-allergic drugs segment dominates the market. The high prevalence of allergic diseases is growing the demand for anti-allergic tablets.
The market is divided into five categories based on Indication: neurological diseases, cardiovascular diseases, gastrointestinal diseases, allergic diseases, and others. The cardiovascular diseases segment dominates the market. ODTs are widely used for treating every cardiovascular disease which boosts segment growth.
The market is divided into three categories based on Distribution Channels: hospital pharmacies, online pharmacies, and others. The hospital pharmacies segment dominates the market and is expected to maintain its high dominance during the forecast period. The online pharmacies segment is estimated to grow at the fastest rate over the forecast period.
Orally Disintegrating Tablet Market- Geographical Insights
Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. North America holds a significant share of the global ODT market, largely due to its advanced healthcare infrastructure and high prevalence of chronic diseases. The Asia-Pacific region is experiencing rapid growth in the ODT market due to rising healthcare access, increasing chronic disease prevalence, and a large patient population. Significant market opportunities in countries like India and China, are driven by high population density and increasing healthcare needs. There is also a growing trend towards domestic pharmaceutical companies developing ODT formulations.
The Orally Disintegrating Tablet (ODT) market is highly competitive, with several key players and ongoing developments shaping its landscape. Market players are developing new ODT formulations with improved taste-masking and faster disintegration times. Innovations in excipient technologies and tablet matrix design are enhancing the overall patient experience. Major pharmaceutical companies are focusing on expanding their ODT product offerings in emerging markets such as Asia-Pacific and Latin America. This expansion is driven by growing healthcare access and increasing demand for patient-friendly medication.
In March 2023, Zydus Cadilla got FDA approval for manufacturing Olanzapine ODT for nervous system diseases.
In June 2022, Catalent and MigVax announced the utilization of Zydis Bio orally disintegrating tablet technology.